Abstract
The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect.
Keywords:
Brizantin; Divaza; release-active antibody-based preparations; vertigo.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Acceleration / adverse effects
-
Adolescent
-
Adult
-
Antibodies / therapeutic use*
-
Coriolis Force
-
Double-Blind Method
-
Drug Combinations
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nausea / etiology
-
Nausea / physiopathology
-
Nausea / prevention & control
-
Nitric Oxide Synthase Type III / immunology
-
Primary Dysautonomias / etiology
-
Primary Dysautonomias / physiopathology
-
Primary Dysautonomias / prevention & control
-
Receptor, Cannabinoid, CB1 / immunology
-
S100 Proteins / immunology
-
Severity of Illness Index
-
Space Motion Sickness / etiology
-
Space Motion Sickness / physiopathology
-
Space Motion Sickness / prevention & control*
-
Vestibule, Labyrinth / drug effects
-
Young Adult
Substances
-
Antibodies
-
Brizantin
-
CNR1 protein, human
-
Dietressa
-
Drug Combinations
-
IMPAZA
-
Receptor, Cannabinoid, CB1
-
S100 Proteins
-
divaza
-
tenoten
-
NOS3 protein, human
-
Nitric Oxide Synthase Type III